IBAB Ion Beam Applications SA

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION

 

 

(Article 14, paragr

aph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, January 31, 2024 01:00

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 25, 2024.

In its notification, NORGES BANK indicated that following an acquisition or disposal of securities or voting rights, downward crossing of the lowest threshold. Its total participation in IBA SA decreased and its participation in IBA shares with voting rights crossed the threshold of 1% on 23/01/2024.

Content of the notification

  • Reason for the notification: Acquisition or disposal of securities or voting rights

Downward crossing of the lowest threshold

  • Notification by: A person notifying alone
  • Persons subject to the notification requirement:
  • Date on which the threshold is crossed: 23/01/2024
  • Threshold crossed (in %) : 1%
  • Denominator : 40.595.290
  • Notified details: (extract of the received notification form)
  • Additional information

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reservesand is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for managementof the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting asprincipal and all holdings are registered in the name of Norges Bank.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

Valérie Van Impe

Paralegal



 

Attachment



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

Guy Sips ... (+5)
  • Guy Sips
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
 PRESS RELEASE

IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiw...

IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan The Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Ph...

 PRESS RELEASE

IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone...

IBA et PET Pharm Bio signe un contrat pour l’installation d’un Cyclone® IKON à Taiwan Le Cyclone® IKON est le cyclotron haute énergie et haute capacité d'IBA qui offre le plus grand spectre d'énergie pour la production d’isotopes TEP et TEMP de 13 MeV à 30 MeV. Louvain-la-Neuve, Belgique, le 21 mai 2025 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et le principal fournisseur de solutions de production de radiopharmaceutiques, annonce avoir signé un contrat avec PET Pharm Bio pour installer un centre de production d'isotopes...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Immediate Release – May 19th, 2025 Louvain-la-Neuve, Belgium, May 19th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March ...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 19 mai 2025 Louvain-la-Neuve, Belgique, 19 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décembr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch